Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.53 |
| ▸ | MAPT | P10636 | 3/20 | 0.53 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.53 |
| ▸ | CASP1 | P29466 | 1/20 | 0.53 |
| ▸ | CASP7 | P55210 | 1/20 | 0.53 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.44 |
| ▸ | GPR3 | P46089 | 1/20 | 0.44 |
| ▸ | HTR6 | P50406 | 1/20 | 0.44 |
| ▸ | BAZ2B | Q9UIF8 | 1/20 | 0.44 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | HPGD | P15428 | 2/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | PSMB8 | P28062 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9979911 | 0.95 | KDM4E (0.50) | KDM4EMAPTHCRTR1CASP1CASP7 | |
| SCHEMBL24611600 | 0.89 | BCHE (0.47) | KDM4EMAPTHCRTR1CASP1CASP7 | |
| SCHEMBL1921474 | 0.89 | GPR3 (0.64) | KDM4EMAPTHCRTR1CASP1CASP7 | |
| SCHEMBL14050151 | 0.88 | BCHE (0.56) | KDM4EMAPTHCRTR1CASP1CASP7 | |
| SCHEMBL13899688 | 0.83 | MAPK8 (0.46) | KDM4EMAPTHCRTR1CASP1CASP7 | |
| SCHEMBL4130418 | 0.83 | KDM4E (0.42) | KDM4EMAPTHCRTR1CASP1CASP7 | |
| SCHEMBL4117448 | 0.82 | KDM4E (0.51) | KDM4EMAPTBAZ2BKCNH2ALDH1A1 | |
| SCHEMBL2183525 | 0.82 | KDM4E (0.41) | KDM4EMAPTHCRTR1CASP1CASP7 | |
| SCHEMBL9979914 | 0.81 | MAT2A (0.49) | KDM4EMAPTHCRTR1CASP1CASP7 | |
| SCHEMBL21782165 | 0.81 | RAB9A (0.55) | KDM4EMAPTHCRTR1CASP1CASP7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11411185-B2 | Organic electroluminescent device | UDC IRELAND LIMITED (IE) | 2022-08-09 | — | — | US | disclosed |
| US-10314816-B2 | Antimicrobial compounds, compositions and methods of use thereof | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2019-06-11 | — | — | US | disclosed |
| WO-2017044569-A1 | HETEROCYCLIC CONSTRAINED TRICYCLIC SULFONAMIDES AS ANTI-CANCER AGENTS | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) | 2017-03-16 | — | — | WO | disclosed |
| US-20160248025-A1 | Organic Electroluminescent Device | UDC IRELAND LTD (IE) | 2016-08-25 | — | — | US | disclosed |
| US-20160248025-A1 | Organic Electroluminescent Device | UDC IRELAND LTD (IE) | 2016-08-25 | — | — | US | disclosed |
| US-9359548-B2 | Organic electroluminescent device | UDC IRELAND LIMITED (IE) | 2016-06-07 | — | — | US | disclosed |
| US-9359548-B2 | Organic electroluminescent device | UDC IRELAND LIMITED (IE) | 2016-06-07 | — | — | US | disclosed |
| US-9133115-B2 | 4-amino-4-oxobutanoyl peptides as inhibitors of viral replication | ACHILLION PHARMACEUTICALS, INC. (US) | 2015-09-15 | — | — | US | disclosed |
| US-20140113890-A1 | NEW 4-AMINO-4-OXOBUTANOYL PEPTIDES AS INHIBITORS OF VIRAL REPLICATION | ACHILLION PHARMACEUTICALS, INC. (US) | 2014-04-24 | — | — | US | disclosed |
| EP-1528074-B1 | NOVEL TRIARYLAMINE POLYMER, PROCESS FOR PRODUCING THE SAME, AND USE THEREOF | TOSOH CORP (JP) | 2014-03-26 | — | — | EP | disclosed |
| US-20100084967-A1 | ORGANIC ELECTROLUMINESCENT DEVICE | FUJIFILM CORPORATION (JP) | 2010-04-08 | — | — | US | disclosed |
| US-20100084967-A1 | ORGANIC ELECTROLUMINESCENT DEVICE | FUJIFILM CORPORATION (JP) | 2010-04-08 | — | — | US | disclosed |
| US-7608680-B2 | Triarylamine polymer, process for producing the same, and use thereof | TOSOH CORPORATION (JP) | 2009-10-27 | — | — | US | disclosed |
| US-20080286605-A1 | efficiency (electric power consumption) and durability; complex is chemical stability | FUJIFILM CORPORATION (JP) | 2008-11-20 | — | — | US | disclosed |
| US-20080286605-A1 | efficiency (electric power consumption) and durability; complex is chemical stability | FUJIFILM CORPORATION (JP) | 2008-11-20 | — | — | US | disclosed |
| US-20060241278-A1 | Novel triarylamine polymer, process for producing the same, and use thereof | TOSOH CORPORATION (JP) | 2006-10-26 | — | — | US | disclosed |
| US-20060017040-A9 | Novel triarylamine polymer, process for producing the same, and use thereof | SUZUKI TAKAO | 2006-01-26 | — | — | US | disclosed |
| EP-1528074-A1 | NOVEL TRIARYLAMINE POLYMER, PROCESS FOR PRODUCING THE SAME, AND USE THEREOF | Tosoh Corporation (JP) | 2005-05-04 | — | — | EP | disclosed |
| US-20040262574-A1 | Novel triarylamine polymer, process for producing the same, and use thereof | TOSOH CORPORATION (JP) | 2004-12-30 | — | — | US | disclosed |
| US-6034206-A | POLYANILINES; HEAT, CHEMICAL AND SOLVENT RESISTANCE | TOSOH CORPORATION (JP) | 2000-03-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10314816-B2 | Antimicrobial compounds, compositions and methods of use thereof | CLPP, ATP5ME, PCNA | KDM4E 4409/4885MAPT 4759/4885HCRTR1 4618/4885 |
| US-20140113890-A1 | NEW 4-AMINO-4-OXOBUTANOYL PEPTIDES AS INHIBITORS OF VIRAL REPLICATION | ZC3HAV1, VIP, ZC3HAV1L | KDM4E 556/4885MAPT 4391/4885HCRTR1 528/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.